Tuesday, July 17, 2012 10:58:58 PM
Not sure why that is funny about drug addiction. Here is a post of abusers talking about how to defeat them
http://www.topix.com/forum/drug/oxycontin/T7BD58FHK59JMQCDJ
Critics allege OxyNEO was introduced in Canada because of impending patent expiry
http://www.thestar.com/news/canada/article/1165664--critics-allege-oxyneo-was-introduced-in-canada-because-of-impending-patent-expiry
Here is what I had remembered. Just google Oxyneo and canada and you can read for hours. Also folks have been trying to inject the stuff and apparently it has killed some folks.
ORONTO - Saskatchewan has joined Ontario and the Atlantic provinces in taking steps to stop funding the painkiller OxyContin, and a new version of the drug, OxyNeo.
The changes coincide with plans by the manufacturer, Purdue Pharma Canada of Pickering, Ont., to discontinue producing OxyContin at the end of February and replace it with OxyNeo.
Starting at the end of the month, Saskatchewan will only pay for OxyNeo for cancer or palliative care patients. Existing patients who have received coverage of OxyContin in the three months prior to March 1 will be eligible for coverage of OxyNeo.
Earlier Tuesday, Nova Scotia Health Minister Maureen MacDonald said cancer patients and those in palliative care who are already prescribed OxyContin would continue to receive the drug.
In a notice released Friday, the Ontario Health Ministry said OxyNeo would be funded through the province's Exceptional Access Program, which places prescriptions of the drug under tighter controls.
http://www.huffingtonpost.ca/2012/02/22/oxycontin-canada-saskatchewan-ontario_n_1292895.html
http://www.topix.com/forum/drug/oxycontin/T7BD58FHK59JMQCDJ
Critics allege OxyNEO was introduced in Canada because of impending patent expiry
http://www.thestar.com/news/canada/article/1165664--critics-allege-oxyneo-was-introduced-in-canada-because-of-impending-patent-expiry
Here is what I had remembered. Just google Oxyneo and canada and you can read for hours. Also folks have been trying to inject the stuff and apparently it has killed some folks.
ORONTO - Saskatchewan has joined Ontario and the Atlantic provinces in taking steps to stop funding the painkiller OxyContin, and a new version of the drug, OxyNeo.
The changes coincide with plans by the manufacturer, Purdue Pharma Canada of Pickering, Ont., to discontinue producing OxyContin at the end of February and replace it with OxyNeo.
Starting at the end of the month, Saskatchewan will only pay for OxyNeo for cancer or palliative care patients. Existing patients who have received coverage of OxyContin in the three months prior to March 1 will be eligible for coverage of OxyNeo.
Earlier Tuesday, Nova Scotia Health Minister Maureen MacDonald said cancer patients and those in palliative care who are already prescribed OxyContin would continue to receive the drug.
In a notice released Friday, the Ontario Health Ministry said OxyNeo would be funded through the province's Exceptional Access Program, which places prescriptions of the drug under tighter controls.
http://www.huffingtonpost.ca/2012/02/22/oxycontin-canada-saskatchewan-ontario_n_1292895.html
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
